Cargando…

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK

INTRODUCTION: Darunavir (DRV) is a preferred agent in treatment guidelines for ART-naïve and experienced patients [1]. It is considered to have a high genetic barrier to resistance and 11 resistance-associated mutations (RAMs) are recognized by IAS-USA [2]. These have largely been identified by anal...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Bouzidi, Kate, White, Ellen, Mbisa, Jean L, Phillips, Andrew, Mackie, Nicola, Pozniak, Anton, Dunn, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P207
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225433/ https://www.ncbi.nlm.nih.gov/pubmed/25397484 http://dx.doi.org/10.7448/IAS.17.4.19739

Ejemplares similares

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2016)

Accuracy of Physical Exam in Covid Era
por: Sunkara, Anusha, et al.
Publicado: (2020)

Caractéristiques épidémiologiques de la pneumonie COVID-19
por: Sahnoun, I., et al.
Publicado: (2022)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy
por: Antinori, Andrea, et al.
Publicado: (2014)

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
por: Lanzafame, Massimiliano, et al.
Publicado: (2014)

Temporomandibular disorders in scuba divers: a systematic review
por: Branco, Carla, et al.
Publicado: (2021)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study
por: Portilla, Joaquín, et al.
Publicado: (2014)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Darunavir in experienced patients
por: Sterrantino, G, et al.
Publicado: (2010)

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013
por: McFaul, Katie, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors
por: Barber, Tristan J, et al.
Publicado: (2014)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor
por: Barber, Tristan, et al.
Publicado: (2014)

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens
por: Wiesmann, Frank, et al.
Publicado: (2014)

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis
por: Zaccarelli, Mauro, et al.
Publicado: (2014)

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
por: Kiselinova, Maja, et al.
Publicado: (2014)

Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
por: Bianco, Claudia, et al.
Publicado: (2014)

Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults
por: Tashima, Karen, et al.
Publicado: (2014)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients
por: Mikula, James M., et al.
Publicado: (2013)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

Service impact of a change in HIV-1 viral load quantification assay
por: Tipple, Craig, et al.
Publicado: (2014)

Structures of Darunavir-Resistant HIV-1 Protease Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Viro-immunological characterization of naïve patients with high cerebrospinal fluid (CSF) HIV RNA
por: Iannuzzi, Francesca, et al.
Publicado: (2014)

Epi-aortic lesions, pathologic FMD, endothelial activation and inflammatory markers in advanced naïve HIV-infected patients starting ART therapy
por: Bellacosa, Chiara, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4mvs3iiboojracsjlr6k7cogrk